Hong Kong · Delayed Price · Currency is HKD Zai Lab Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed a quorum and approved all fourteen proposals, including director reelections, auditor appointments, executive compensation, and mandates for share issuance and repurchase. No shareholder questions were raised, and all resolutions passed as ordinary resolutions.
-
Q1 revenue declined 6% year-over-year to $99.6M, with near-term pressure expected through 2026 and a return to growth in 2027. Pipeline advances include strong zoci data, new collaborations, and upcoming launches, supported by a robust cash position.
-
Zoci demonstrated high intracranial response rates and durable efficacy in small cell lung cancer with brain metastases, as well as meaningful activity in extrapulmonary neuroendocrine carcinomas, regardless of DLL3 status. Ongoing trials and new combinations aim to establish zoci as a backbone therapy across these indications.
-
The company is rapidly evolving into a global biopharma, advancing a diverse pipeline led by a DLL3 ADC in phase III for small cell lung cancer, with strong efficacy and safety data. Multiple innovative ADCs and immunotherapies are entering the clinic, and global commercialization strategies are being developed for oncology and autoimmune assets.
-
A dual-engine strategy drives growth, with a profitable China business funding a robust global pipeline focused on immunology and oncology. Lead asset Zoci shows strong efficacy in small cell lung cancer, while new launches like COBENFY and VYVGART fuel commercial expansion. Financial strength and disciplined investment support a catalyst-rich outlook for 2026.
Fiscal Year 2025
-
Revenue grew 15% year-over-year in 2025, driven by strong commercial performance and pipeline progress. 2026 will focus on execution, new launches, and advancing late-stage assets, with profitability targeted as a key objective.
-
Q3 2025 revenue rose 14% year-over-year to $116.1M, led by Nuzyra and VYVGART, while profitability is now expected beyond Q4 due to a slower ramp in China. Zoci advanced to pivotal trials, and the pipeline remains robust with strong cash reserves supporting growth.
-
Zoci, a DLL3-targeted ADC, showed a 68% ORR and strong safety in heavily pretreated small cell lung cancer, including patients with brain metastases. A pivotal phase 3 trial is underway, with accelerated approval targeted for 2027 and expansion into first-line and neuroendocrine carcinoma indications planned.
-
The conference highlighted a robust pipeline with key assets in oncology, immunology, and neurology, including DLL3 ADC targeting small cell lung cancer and POVI for IgAN nephropathy. Commercial strategies leverage China’s evolving biotech landscape, with major product launches and regulatory milestones expected over the next 12–18 months.
-
Strong commercial growth in China and a robust global pipeline are driving a target of $2 billion in sales by 2028. Key products like VYVGART, COBENFY, and DLL3 ADC are expected to deliver significant revenue, with regulatory and pricing strategies supporting long-term growth.
-
Q2 2025 revenue rose 9% to $110M, with operating loss improving 28% and adjusted loss down 37%. Vyvgart and Xacduro drove growth, while Zejula is expected to rebound in H2. Profitability is targeted for Q4, with strong cash reserves and multiple late-stage pipeline milestones ahead.
-
Sales are expected to grow over 40% in 2025, driven by Vivgaard's rebound and new launches, with profitability targeted by year-end. Strong clinical data for the DLL3 ADC supports pivotal studies and potential accelerated approval in 2027, while the pipeline expands in oncology and immunology.
-
Updated phase I data for ZL1310 in recurrent small cell lung cancer show high response rates, durable benefit, and a favorable safety profile, especially at the 1.6 mg/kg dose. A pivotal phase III trial is planned, with accelerated approval targeted for 2027 and expansion into other neuroendocrine tumors underway.
-
ZL1310 showed strong efficacy and a favorable safety profile in phase 1 for relapsed small cell lung cancer, with the 1.6 mg/kg dose emerging as optimal. A pivotal phase 3 trial is planned, and regulatory discussions for accelerated approval are ongoing.
-
Q1 2025 revenue rose 22% year-over-year to $106.5M, with operating loss improving 20% and adjusted loss down 25%. Full-year revenue guidance of $560M–$590M was reaffirmed, with profitability targeted by Q4 2025 and strong pipeline progress highlighted.
-
Management outlined a profitable China business, robust global pipeline, and key 2025 milestones including VYVGART sales growth, pivotal DLL3 ADC trial, and Q4 profitability. Policy reforms and business development support long-term growth and margin expansion.
-
The summit highlighted a robust oncology pipeline, with ZL-1310 (DLL3 ADC) showing high response rates and rapid development in small cell lung cancer, alongside pivotal trials for bemarituzumab in gastric cancer. Non-oncology assets and innovative modalities are advancing, with strategic flexibility for partnerships.
-
Achieved commercial profitability and expect overall corporate profitability by Q4 2024, with $2 billion annual revenue targeted by 2028. Multiple blockbuster launches, a robust pipeline, and operational efficiencies are driving growth, while strategic partnerships and disciplined R&D investment support long-term expansion.
Fiscal Year 2024
-
Achieved 50% revenue growth in 2024, driven by VYVGART and new launches, with strong operational efficiency and a robust pipeline. Guidance for 2025 projects $560–$590 million in revenue and profitability by Q4, supported by continued product expansion and clinical milestones.
-
The event detailed robust commercial growth in China, with Vyvgart and Zejula as key drivers and a strong pipeline including DLL3, KarXT, and Bemirituzumab. Profitability is targeted by 2025, with global expansion and ongoing business development supported by recent capital raising.
-
Q3 2024 saw 47% revenue growth, led by Vyvgart's strong launch and expanding pipeline progress. Net loss improved 40% year-over-year, with profitability targeted by end of 2025 and multiple product launches ahead.
-
ZL-1310 demonstrated a 74% response rate in recurrent small cell lung cancer, including patients with brain metastases and those previously treated with tarlatamab, with a favorable safety profile and rapid, durable responses. Dose optimization and global expansion are underway, with plans for accelerated approval and combination studies.
-
Management outlined a vision for 50% annual sales growth to $2 billion by 2028, driven by a robust product portfolio and new launches in China. Profitability is targeted for Q4 2025, with continued expansion into global markets and a focus on innovative therapies.
-
Q2 2024 net product revenues rose 45% year-over-year to $101 million, led by VYVGART's strong launch and portfolio growth. Profitability is targeted by end of 2025, with 50%+ annual revenue growth and new product launches expected to drive future performance.
-
The company is executing a five-year growth plan with strong VYVGART launch momentum, expanding its sales force and pipeline, and targeting new indications like CIDP. Profitability is supported by improved pricing and operational efficiency, with a robust cash position to fund growth and R&D through 2025.